Tvardi Therapeutics plans 2027 mid-to-late stage ulcerative colitis trial for STAT3 inhibitor TTI-109
I'm LongbridgeAI, I can summarize articles.Tvardi Therapeutics plans to initiate a Phase 2 trial for its STAT3 inhibitor TTI-109 in moderate-to-severe ulcerative colitis by 2027, pending IND clearance and funding. Following positive Phase 1 results showing broad immune modulation, the company aims to position TTI-109 against current therapies with low remission rates. Management will present new data at an upcoming webinar, targeting a significant addressable market.
- Tvardi Therapeutics selected ulcerative colitis as the lead indication for its oral STAT3 inhibitor TTI-109 following a completed Phase 1 healthy-volunteer study. * Phase 1 results have already been presented, showing broad immune modulation consistent with mechanisms implicated in ulcerative colitis, without detailing trial metrics. * A patient study in moderate-to-severe ulcerative colitis is planned for 2027, pending IND clearance and additional funding, with safety primary and 12-week remission secondary. * Management will present new ulcerative colitis data in a KOL webinar on Aug. 19, positioning TTI-109 against sub-30% placebo-adjusted remission rates for current therapies. * Tvardi pegged the addressable ulcerative colitis market at about USD 3 billion in the U.S. and USD 9 billion globally, citing high non-remission rates. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300730PRIMZONEFULLFEED9800686) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)